Author: Michael

Photo by Patrick McDermott/Getty Images
Favre wants a federal court to allow his case against Sharpe to continue.
It’s been a while since we heard from the ol’ gunslinger Brett Favre. Still embroiled in legal issues related to his alleged role in a welfare fraud scheme in Mississippi, Favre is on the offensive this time as his lawyers are asking a federal appeals court to reinstate his defamation suit against Shannon Sharpe.

Read More

Photo by Brian Babineau/NBAE via Getty Images
Who Embiid plays for at the Olympics has become the stupidest internet argument.
The 2024 Olympic games in Paris is going to be a statement for Team USA men’s basketball. Years of hearing how the “world is catching up” and one year removed from a pathetic fourth place showing at the FIBA World Cup has lit a fire under the United State to prove its still the dominant global force in basketball, and that nobody can touch Team USA when it sends its best players.

Read More

Novak Djokovic says tennis is “endangered.” And there’s one major culprit spearheading its demise… pickleball.
“If we don’t do something about it, globally or collectively, paddle — pickleball in the States — they’re gonna convert all the tennis clubs into paddle and pickleball,” Djokovic told reporters at Wimbledon.
The world No. 2 men’s singles player explained that his sport has to do a better job of marketing to grow its audience — particularly, the younger demographic.

Read More

Zach Edey brought big boy ball back to NBA summer league
No one expected Zach Edey to become a top-10 NBA Draft pick at any point during his historically dominant college career at Purdue, but the Memphis Grizzlies had a different vision. The Grizzlies needed a center to set screens for Ja Morant, gobble up rebounds for Jaren Jackson Jr., and finish efficiently inside. Edey checked all of those boxes, so the Grizzlies made a leap of faith by taking him at No. 9 overall.

Read More

Shares of Novo Nordisk (NVO) are falling after a new study found that Eli Lilly’s (LLY) GLP-1 weight-loss drug tirzepatide (Mounjaro) leads to faster and greater weight loss results than semaglutide (Ozempic). Yahoo Finance Senior Reporter Anjalee Khemlani breaks down the study and how it’s affecting Novo Nordisk’s stock valuation. For more expert insight and the latest market action, click here to watch this full episode of Morning Brief.

Read More